AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01282684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLX5622
Description: PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo
Study NCT01282684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for PLX5622.
Study NCT01796392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBV
Description: This study arm will undergo EBV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
Study NCT01796392 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Optimal Medical Management
Description: This study arm will receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
Study NCT04220788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced pharmacist service
Description: Calculation of cardiovascular risk by an online tool for discussion on the CVD risk. Pharmacist will also provide ducation on cardiovascular risk factors and healthy lifestyle. Any prescription adaptation(s), and/or recommendations where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation will be initiated
Study NCT04220788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants in the arm will receive their care from their respective nurse, doctor or pharmacists as per usual clinic practice
Study NCT01820598 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Multisite NMES training during 6 weeks
Study NCT05289336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Laser Microsurgery
Study NCT00261209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase
Description: Collagenase injection into adhesion restricting tendon gliding
Study NCT00261209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase injection
Description: injection of collagenase into adhesion restricting tendon gliding
Study NCT02691052 — intervention group
Intervention type: OTHER
Intervention: Quality of Life questionnaire
Description: EORTC QLQ-C30 questionnaire
Study NCT06041451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulins, Human
Description: patients were treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days
Study NCT06041451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 500 MG Injection
Description: patients were treated with methylprednisolone
Study NCT01148680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Islet Graft
Description: Iterative injection of pancreatic islets (minimum: 250,000 IEQ / injection or 3500 IEQ / kg / injection) with a threshold required total of 11,000 IEQ / kg in 2 or 3 injections per patient)
Study NCT02945085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Based Care Team
Description: Clinical team will conduct comprehensive clinical assessments focused on cognitive impairment and depression, conduct comprehensive medication review and reconciliation, offer Problem Solving Therapy, and offer brief occupational therapy, physical therapy, nutrition, and social support services.
Study NCT02945085 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Based Care Team
Description: Telephone contact will be made by nurses. Depending on level of need, follow up telephone and, in some cases, in home visits will be made by nurse or social worker from care management program.
Study NCT03526900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: * Induction (four or six 21-day cycles) : Atezolizumab 1200 mg / iv + carboplatin 5 AUCs + pemetrexed 500 mg/m2~* Maintenance (21-day cycles): atezolizumab 1200 mg/iv + pemetrexed 500 mg/m2.
Study NCT03750318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vital sign monitoring
Description: Each patient will be set up for monitoring on admission. Duration of opioid therapy for post-operative in-patients may range from 1-3 days. Once opioid therapy is no longer required, Aingeal monitoring will be ended and each patient would be encouraged to have at least 1 day Aingeal monitoring to be recorded during the study. De-identified log files will be extracted from the Surveillance Station and reprocessed to produce counts of the number of alarms raised during monitoring. A sample of the data will be reviewed to determine whether cardiac and respiratory alarms are defined as True or False, with an overall Alarm Rate per patient per day and False Positive Alarm Rate per patient per day derived. Vital sign trend graphs for each patient will be produced.
Study NCT06636305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity intervention
Description: Women in the intervention group were instructed to obtain 10,000 steps per day and 150 minutes of MVPA (defined as physical activity that resulted in a heart rate in the range of 120-170 bmp) per week and were given a physical activity tracker (FitBit Charge HR 2, Fitbit, San Francisco, USA) to self-monitor progress.
Study NCT00593931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Functional Magnetic Resonance Imaging without contrast
Study NCT02475980 — intervention group
Intervention type: BEHAVIORAL
Intervention: Comprehensive contraception counseling
Description: The study intervention will consist of comprehensive contraceptive counseling through a standardized bundle of services, including a 10-minute educational DVD, handouts on contraceptive methods, and one-on-one contraceptive counseling by the PED physician.
Study NCT02862535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered via intravenous (IV) infusion (approximately 30 minutes)
Study NCT02862535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Administered orally
Study NCT02862535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered via IV infusion on Day 8 of every 5 weeks
Study NCT02862535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered via IV infusion for over 2 hours on Day 1 of each 21-day cycle
Study NCT02091999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin
Description: intravenous (IV) infusion
Study NCT03246360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modification for administration mode of cloxacillin antibiotic
Description: For intermittent administration, patients will benefit from cloxacillin treatment in conventional hospitalization, in accordance with national guidelines, at a dose of 150 mg / kg per day in 4 infusions, not exceeding the maximum daily dose of 12 g / day according to.~For continuous administration the same quantity of cloxacillin 150 mg / kg per day, without exceeding the maximum daily dose of 12 g / day, will be delivered by a self-propelled syringe in twice 12 hours. Patients randomly assigned to receive continuous administration will receive a dose of cloxacillin equivalent to the dose administered 4 times daily during iterative administration using a self-pulsating syringe. For the first day of the study, this loading dose will be subtracted from the 150 mg / kg dose to be administered continuously over the remaining 23 hours of the first day of the study and never exceed 12g / day.~Pharmacological dosages will be performed on the third and sixth day in both arms
Study NCT03246360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modification for administration mode of cloxacillin antibiotic
Description: For intermittent administration, patients will benefit from cloxacillin treatment in conventional hospitalization, in accordance with national guidelines, at a dose of 150 mg / kg per day in 4 infusions, not exceeding the maximum daily dose of 12 g / day according to.~For continuous administration the same quantity of cloxacillin 150 mg / kg per day, without exceeding the maximum daily dose of 12 g / day, will be delivered by a self-propelled syringe in twice 12 hours. Patients randomly assigned to receive continuous administration will receive a dose of cloxacillin equivalent to the dose administered 4 times daily during iterative administration using a self-pulsating syringe. For the first day of the study, this loading dose will be subtracted from the 150 mg / kg dose to be administered continuously over the remaining 23 hours of the first day of the study and never exceed 12g / day.~Pharmacological dosages will be performed on the third and sixth day in both arms
Study NCT01722591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiapex device
Description: Cardiapex percutaneous transapical access and closure system
Study NCT02842398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Master
Study NCT02842398 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Customary Care
Study NCT03758898 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment
Description: Chest physiotherapy and mobilization were applied twice a day, 8 times in total.
Study NCT03758898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Chest physiotherapy and mobilization were applied twice a day, 8 times in total.
Study NCT03758898 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group 2
Description: Only mobilization was applied twice a day, 8 times in total.
Study NCT03758898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2
Description: Only mobilization was applied twice a day, 8 times in total.
Study NCT01807273 — intervention group
Intervention type: OTHER
Intervention: Walking test
Study NCT03116139 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: V/Q imaging
Description: Standard of care
Study NCT03116139 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Computed tomography scan
Description: Standard of care
Study NCT00216151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Zoledronic Acid 4mg, every three months
Study NCT04498650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ912
Description: PQ912 50 mg tablets and 150 mg tablets
Study NCT04498650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to mimic PQ912 50 mg and 150 mg tablets
Study NCT02219932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fampridine
Study NCT02219932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT01595919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Ad libitum amounts of beverage at a meal
Study NCT03785418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Risk Factor Modification
Description: Healthy eating, regular exercise and behavioural therapy.
Study NCT01863888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriflunomide HMR1726
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT01863888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholestyramine
Description: Pharmaceutical form:powder Route of administration: oral
Study NCT01863888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: charcoal
Description: Pharmaceutical form:granule Route of administration: oral
Study NCT01391234 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: STAT RT planning and delivery workflow
Description: * Patients will receive simulation, planning, quality assurance, and their first treatment in a single day using the STAT RT workflow.~* Patients will receive a total of 1-5 fractions of high dose palliative radiation therapy via TomoTherapy consisting of 5-10 Gray per fraction.~* Data will be collected to evaluate the effectiveness of our novel image co-registration techniques, CT-detector-based exit dose calculations, and infrared patient position monitoring. These novel techniques for image co-registration, radiation dose calculations, and patient position monitoring will not alter or replace standard of care techniques.
Study NCT02253589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified ASSIST-linked Brief Intervention
Description: Trained counsellors support participant's motivation to reduce or stop khat use in a 20 minute counselling session.
Study NCT02862535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered via IV infusion (approximately 60 minutes) every 2 weeks
Study NCT05762978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-Check Dial
Description: Patient will have their NIF measured with In-Check Dial
Study NCT05762978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler Device
Description: Children will use inhaler per standard of care.
Study NCT03379428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg loading dose (first dose), followed by 6 mg/kg every 3 weeks, administered intravenously (IV)
Study NCT04660409 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood test for serum Adropin
Description: Blood test for serum Adropin
Study NCT03791918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Study NCT03791918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: 3mg/kg intravenously every 2 weeks
Study NCT03791918 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. TACE Drug Protocol were injected.
Study NCT03791918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE Drug Protocol
Description: lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
Study NCT04058431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: Osteopathic manipulative treatment (OMT) is defined as the therapeutic application of manually guided forces by an osteopathic physician to improve physiologic function and/or support homeostasis that has been altered by somatic dysfunction. Somatic (body framework) dysfunction or altered function of related components is observed in the skeletal, arthrodial and myofascial structures, and their related vascular, lymphatic, and neural elements. Techniques can use a direct method where the restrictive barrier is engaged and a final activating force is applied to correct the somatic dysfunction, or an indirect method where the restrictive barrier is disengaged and the dysfunctional body part is moved away from the restrictive barrier until tissue tension is equal in one or all planes and directions
Study NCT04058431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control- No Intervention
Description: This group will refrain from getting OMT while in the study.
Study NCT03398460 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Survey
Description: Burnout rates before and after the introduction of a bereavement card Burnout rates before and after an ICU rotation for physicians
Study NCT00849524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISF35
Description: Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10\^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
Study NCT03763617 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: d-ptfe membrane
Description: Socket preservation using d-ptfe membrane to inhibit the formation of osteoclasts
Study NCT03677635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Autobiographical Memory Recall
Description: Participants are asked to recall positive autobiographical memories with the assistance of prompts to promote specificity, generalisability and links to the future. The participants will also view a 5min psychoeducation video on the subject of memory specificity and motivation.
Study NCT02407756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Study NCT01938521 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Grape Cells (RGC)
Description: Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
Study NCT01938521 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Red Grape Cells (RGC))
Description: Placebo (for Red Grape Cells (RGC)) powder manufactured to mimic Red Grape Cells (RGC) 1000 mg powder
Study NCT01922037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Participants will receive omalizumab for up to 12 months per investigator standard of care and clinical practice.
Study NCT01436669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Telemonitoring System (The Zodiac, Philips Health care)
Description: Full blood count (FBC) home tele-monitoring system which will allow cancer patients receiving chemotherapy to test their blood count at home (haemoglobin, haematocrit, white cell count and neutrophil count).
Study NCT01503242 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation
Study NCT01503242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study NCT01503242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01503242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO
Study NCT01503242 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation
Study NCT01503242 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT01503242 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
Description: Given IV
Study NCT01710878 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intergard Synergy Graft
Study NCT04523831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin and Doxycycline
Description: Ivermectin 6 mg, 2 tab stat and Doxycycline 100 mg twice daily for 5 days
Study NCT04523831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Paracetamol, Vitamin D, Oxygen if indicated, Low molecular weight heparin, dexamethasone if indicated
Study NCT04523831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Paracetamol, Vitamin D, Oxygen if indicated, Low molecular weight heparin, dexamethasone if indicated
Study NCT00624975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peru-15 Vaccine
Description: up to 1 x 10\^9 CFU of Peru-15 given in 5ml single dose vials with 20 ml buffer solution, given once
Study NCT00624975 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 mL of buffer solution (2.5 g sodium bicarbonate and 1.65 g ascorbic acid per 100mL potable water)
Study NCT00546832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDS-943 (topical diclofenac sodium 4% spray)
Study NCT00546832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Study NCT00546832 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04657237 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral block
Description: TPVB will be given using high frequency linear U/S transducer, place the U/S ultrasound probe was placed parallel to the vertebral spine at T4, and, T6 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle was inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 0.25% bupivacaine (20 ml) delivery slowly divided equally at T4and T6; the pleura will be seen to be pushed downward
Study NCT00338494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: The starting dose of clofarabine will be 10 mg/m2 once a week for 3 weeks repeated every 4 weeks with dose escalations to 15, 20 , 30 and 40 mg/m2/week.
Study NCT02289027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBOZ vaccine
Study NCT02289027 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for cAd3-EBOZ vaccine)
Description: Diluent
Study NCT01899482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage
Study NCT01418352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole tablets once weekly for 8 weeks.